Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Average Recommendation of "Buy" from Brokerages

Key Points

• Avalo Therapeutics, Inc. has received an average recommendation of "Buy" from seven research firms, with an average target price of $30.00.
• Despite the optimistic ratings, Avalo Therapeutics reported a loss of $1.92 per share in its recent earnings, which was below the consensus estimate.
• Institutional investors hold 87.06% of Avalo Therapeutics' stock, indicating strong backing from major financial players.

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) has been given an average recommendation of "Buy" by the seven research firms that are currently covering the firm, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $30.00.

Several equities analysts recently issued reports on AVTX shares. Cantor Fitzgerald started coverage on shares of Avalo Therapeutics in a report on Friday, August 15th. They issued an "overweight" rating on the stock. HC Wainwright raised shares of Avalo Therapeutics from a "hold" rating to a "buy" rating and set a $15.00 price objective on the stock in a research report on Monday, June 2nd.

Institutional Trading of Avalo Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AVTX. Tower Research Capital LLC TRC increased its position in Avalo Therapeutics by 998.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company's stock valued at $31,000 after buying an additional 3,754 shares in the last quarter. Quadrature Capital Ltd bought a new stake in Avalo Therapeutics in the 2nd quarter valued at about $55,000. Boothbay Fund Management LLC bought a new stake in Avalo Therapeutics in the 2nd quarter valued at about $56,000. ADAR1 Capital Management LLC bought a new stake in Avalo Therapeutics in the 1st quarter valued at about $80,000. Finally, Marshall Wace LLP bought a new stake in Avalo Therapeutics in the 4th quarter valued at about $114,000. 87.06% of the stock is owned by institutional investors.

Avalo Therapeutics Stock Performance

AVTX stock opened at $9.37 on Friday. Avalo Therapeutics has a 12-month low of $3.39 and a 12-month high of $16.00. The company's fifty day simple moving average is $6.42 and its 200 day simple moving average is $6.09.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($1.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.49). Sell-side analysts expect that Avalo Therapeutics will post -19.07 EPS for the current fiscal year.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.